IRX-2 is a primary cell-derived biologic immunotherapy. Data collected to date suggest that IRX-2 reduces the immune suppression that is often seen in the cancer tumor microenvironment. This immunomodulatory activity appears to occur through the restoration of immune function and activation of a coordinated immune response against the tumor. IRX-2 is a proprietary therapeutic containing numerous active cytokine components, which restore and activate multiple immune cell types, including T cells, dendritic cells, and natural killer cells, that are able to recognize and destroy tumors and protect these activated cells from tumor-induced immunosuppression.1-5
An increase in tumor activation markers, including programmed death-ligand 1 (PD-L1), after IRX-2 administration6 suggests a complementary role of IRX-2 with checkpoint inhibitors.
In squamous cell cancer of the head and neck, (SCCHN), IRX-2 is thought to
IRX-2 is produced under pharmaceutical Good Manufacturing Practices standards from healthy donor mononuclear cells (allogeneic source). No patient blood or tissue is acquired.